The EuroHYP-1 trial is a pan-European, open, randomised, phase III clinical trial which will assess the benefit of therapeutic cooling in adult patients with acute ischaemic stroke. In addition to efficacy and safety, the economic impact of therapeutic hypothermia will be also evaluated.
The EuroHYP consortium brings together leading European experts in statistical design and analysis, therapeutic hypothermia, imaging, health economics, ultrasound, biomarkers, and trial execution (implementation and monitoring) as well as European patient and family advocacy groups and Small and Medium-size Enterprises.
Patient enrolment (31.03.2017)
The EuroHYP-1 trial has been actively recruiting since August 2013. By 31 March 2017, 26 sites were active and 80 patients have been enrolled. For the news about the safety and tolerability of therapeutic cooling please see the Press Releases in several languages, under the “Press Information” menu.